Founder Bankers: Why Nelson Advisors Leads Europe's Lower to Mid-Market HealthTech, MedTech and Health AI M&A

NA

Nov 17, 2026By Nelson Advisors

Selling a healthcare technology company is the most consequential transaction most founders will ever make. It is also, for most of them, the first. Years of product decisions, regulatory submissions, hospital pilots and difficult funding rounds are compressed into a process that lasts a few months and is decided by a handful of conversations.
  
In that process the founder is usually the least experienced person in the room. The acquirer's corporate development team has done this many times. The private equity sponsor does it for a living. The lawyers on both sides have a precedent for every clause. The founder has one company, one outcome and no second attempt.
  
That imbalance is why the choice of adviser matters so much. Yet the traditional model of investment banking was never designed for this client. It was built around large corporates and large fees, and it is staffed by career financiers who have advised on many businesses and built none.
  
Nelson Advisors was founded to offer something different. We are a London-based boutique dedicated exclusively to mergers, acquisitions, partnerships and investments across HealthTech, MedTech, Digital Health, Healthcare IT and Health AI. We focus on the lower to mid market, broadly $25M to $250M in enterprise value. And we are led by people who have founded, scaled and sold healthcare technology companies themselves.
  
We call that model the founder banker. This article explains what the term means, why it produces better outcomes for founders and shareholders, and why we believe the combination of founder experience and single-sector focus has made Nelson Advisors Europe's leading adviser in this part of the market.

Source: https://www.healthcare.digital/single-post/founder-bankers-why-nelson-advisors-leads-europe-s-lower-to-mid-market-healthtech-medtech-and-heal